Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

SEPTEMBER 19, 2019

Here are three of the most pressing matters that might give Congress absolutely no choice but to surrender to marijuana legalization in the interest of public health and safety. . . “ It is already causing a slew of problems in states across the nation. Reason #1: Police confused on how to distinguish the difference between?

Vaping 55

Vaping Hemp Education Patients 55

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. Sessions wrote. “In 2 1 U.S.C. § 801 et seq. It has established significant penalties for these crimes. 2 1 U.S.C. §

Banking 45

Banking Law Marijuana State Laws 45